MedTrace Logo

A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP

NCT01915953 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2013-08-06

No results posted yet for this study

Summary

The purpose of the study is to define the precision, accuracy and variability of the NBM-200 system in non invasive blood Hemoglobin (Hb) measurements relative to the laboratory blood analyzer by comparing two consecutive Hb values obtained by the NBM system to venous values.

Conditions

Sponsors & Collaborators

  • OrSense, Ltd.

    lead INDUSTRY

Principal Investigators

  • Abraham Korenberg, MD · Assaf-Harofeh Medical Center

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915953 on ClinicalTrials.gov